Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences (FBRX) Liabilities and Shareholders Equity (2016 - 2020)

Historic Liabilities and Shareholders Equity for Forte Biosciences (FBRX) over the last 5 years, with Q3 2020 value amounting to $22.7 million.

  • Forte Biosciences' Liabilities and Shareholders Equity fell 6787.23% to $22.7 million in Q3 2020 from the same period last year, while for Dec 2020 it was $69.7 million, marking a year-over-year decrease of 7303.35%. This contributed to the annual value of $7.7 million for FY2019, which is 9257.09% down from last year.
  • Forte Biosciences' Liabilities and Shareholders Equity amounted to $22.7 million in Q3 2020, which was down 6787.23% from $28.3 million recorded in Q2 2020.
  • Forte Biosciences' 5-year Liabilities and Shareholders Equity high stood at $110.8 million for Q2 2017, and its period low was $7.7 million during Q4 2019.
  • Over the past 5 years, Forte Biosciences' median Liabilities and Shareholders Equity value was $82.0 million (recorded in 2018), while the average stood at $66.4 million.
  • Per our database at Business Quant, Forte Biosciences' Liabilities and Shareholders Equity surged by 16045.37% in 2017 and then tumbled by 9257.09% in 2019.
  • Over the past 5 years, Forte Biosciences' Liabilities and Shareholders Equity (Quarter) stood at $35.4 million in 2016, then skyrocketed by 160.45% to $92.1 million in 2017, then increased by 11.96% to $103.1 million in 2018, then tumbled by 92.57% to $7.7 million in 2019, then soared by 196.81% to $22.7 million in 2020.
  • Its Liabilities and Shareholders Equity stands at $22.7 million for Q3 2020, versus $28.3 million for Q2 2020 and $18.6 million for Q1 2020.